-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have shown high efficacy, but participants with weakened immune systems have been excluded from controlled clinical trials
immunity
Recently, a research article was published in the top medical journal Nature Medicine.
After the first vaccination, neutralizing antibodies were detected in 67% of cancer patients.
Within one week after the third vaccination, the median neutralizing antibody response of the 16 participants increased three-fold, but no improvement in T cell response was observed, and adverse events were mild
These results indicate that the third dose of BNT162b2 vaccination is safe, can improve humoral immunity against SARS-CoV-2, and may have immunological benefits for cancer patients receiving active chemotherapy
The third dose of BNT162b2 vaccination is safe, can improve humoral immunity against SARS-CoV-2, and may have immunological benefits for cancer patients receiving active chemotherapy
Original source:
Rachna T.